<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Noninfectious complications of continuous peritoneal dialysis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Noninfectious complications of continuous peritoneal dialysis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Noninfectious complications of continuous peritoneal dialysis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca J Schmidt, DO, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sean Armstrong, MD, FRCPC, MEd</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Some of the noninfectious complications that occur in patients on continuous peritoneal dialysis (eg, continuous ambulatory peritoneal dialysis [CAPD] and continuous cycler peritoneal dialysis [CCPD]) are due to increased intra-abdominal pressure resulting from instillation of dialysate into the peritoneal cavity. These include hernia formation, leaks (including hydrothorax or pleuroperitoneal leaks), local edema, back pain, and gastrointestinal problems, such as gastroesophageal reflux and delayed gastric emptying (see  <a class="medical medical_review" href="/z/d/html/1865.html" rel="external">"Abdominal wall hernia and dialysate leak in peritoneal dialysis patients"</a> and  <a class="medical medical_review" href="/z/d/html/1883.html" rel="external">"Noninfectious complications of peritoneal dialysis catheters"</a>). Complications of CAPD/CCPD not specifically related to intra-abdominal pressure include hemoperitoneum, pain on infusion or drainage of dialysate, electrolyte imbalances, and ultrafiltration failure.</p><p>Some of these problems will be reviewed here, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Gastroesophageal reflux and delayed gastric emptying</p><p class="bulletIndent1"><span class="glyph">●</span>Back and abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Pleural effusion</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoperitoneum</p><p class="bulletIndent1"><span class="glyph">●</span>Infusion and drain pain</p><p class="bulletIndent1"><span class="glyph">●</span>Hypokalemia</p><p class="bulletIndent1"><span class="glyph">●</span>Disorders of magnesium</p><p></p><p>Additional noninfectious complications are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1973.html" rel="external">"Inadequate solute clearance in peritoneal dialysis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1865.html" rel="external">"Abdominal wall hernia and dialysate leak in peritoneal dialysis patients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1883.html" rel="external">"Noninfectious complications of peritoneal dialysis catheters"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">GASTROESOPHAGEAL REFLUX DISEASE AND DELAYED GASTRIC EMPTYING</span><span class="headingEndMark"> — </span>Nausea, vomiting, a sensation of fullness, and epigastric discomfort are commonly reported by patients on continuous ambulatory peritoneal dialysis (CAPD) [<a href="#rid1">1-3</a>]. Gastrointestinal complaints, such as nausea and fullness, occur in as many as 20 to 40 percent of CAPD patients, while approximately 14 percent report frequent vomiting [<a href="#rid1">1,2</a>].</p><p>However, a paucity of data exists concerning the relationship between these symptoms and the presence of gastroesophageal reflux disease (GERD) or delayed gastric emptying (gastroparesis). There are many potential causes of such symptoms, including uremia, medication-induced gastroenteritis, gastritis, and peptic ulcer disease. (See  <a class="medical medical_review" href="/z/d/html/2537.html" rel="external">"Approach to the adult with nausea and vomiting"</a> and  <a class="medical medical_review" href="/z/d/html/2265.html" rel="external">"Clinical manifestations and diagnosis of gastroesophageal reflux in adults"</a>.)</p><p>If the patient is well dialyzed (ie, has an adequate Kt/V) and specific gastrointestinal causes of the symptoms have been excluded, persistent upper gastrointestinal symptoms should prompt consideration of GERD or gastroparesis (see  <a class="medical medical_review" href="/z/d/html/1968.html" rel="external">"Prescribing peritoneal dialysis"</a>). Medical management of both GERD and gastroparesis is similar to that in patients not on dialysis. Successful treatment of these problems is important since, if left untreated, they have a significant adverse effect upon the well-being and nutritional status of peritoneal dialysis patients. (See  <a class="medical medical_review" href="/z/d/html/1856.html" rel="external">"Pathogenesis and treatment of malnutrition in patients on maintenance hemodialysis"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Gastroesophageal reflux disease</span><span class="headingEndMark"> — </span>The general pathophysiology of gastrointestinal reflux is discussed separately (see  <a class="medical medical_review" href="/z/d/html/2257.html" rel="external">"Pathophysiology of reflux esophagitis"</a>). Among peritoneal dialysis patients, there are conflicting data concerning the effects of increased intra-abdominal pressure on lower esophageal sphincter pressures and/or reflux [<a href="#rid4">4,5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study of 11 patients on CAPD, no systematic changes in intragastric or lower esophageal sphincter pressures, as determined by esophageal manometric studies, were observed in response to infusion of 1.5 to 2.5 liters of dialysate [<a href="#rid4">4</a>]. Although eight of these patients had chronic complaints of upper gastrointestinal symptoms, their findings on esophageal manometry were the same as those of the three who were asymptomatic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study of 13 CAPD patients (four patients who had chronic nausea and vomiting and nine who were asymptomatic) also found no difference in supine lower esophageal sphincter pressures between the two groups after 2 liters of infused dialysate [<a href="#rid5">5</a>]. However, compared with asymptomatic individuals, symptomatic patients were observed to have a significantly higher number of reflux episodes (89 versus 17); reflux episodes lasting &gt;5 minutes (2.3 versus 0.3); and an increased time in which the gastric pH was &lt;4 (75 versus 11 minutes), as determined by 24-hour esophageal pH monitoring [<a href="#rid5">5</a>]. These data suggest that GERD is common in symptomatic CAPD patients if the diagnosis is based upon 24-hour gastric pH monitoring rather than findings with esophageal manometry.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective cohort study from Taiwan using a national database including nearly 1900 peritoneal dialysis patients and 8955 hemodialysis patients found that the risk for gastroesophageal reflux, intestinal obstruction or adhesions, and abdominal hernia was significantly higher among peritoneal dialysis patients [<a href="#rid6">6</a>]. Even after propensity score, age, and sex matching, GERD was significantly more common among peritoneal dialysis patients (hazard ratio 2.25, versus hemodialysis patients) [<a href="#rid6">6</a>]. The authors implicate increased abdominal pressure with peritoneal dialysis as the mechanism for the observed higher risk of GERD in peritoneal dialysis patients.</p><p></p><p class="headingAnchor" id="H4"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>In addition to general measures, the treatment of GERD in CAPD/continuous cycler peritoneal dialysis (CCPD) patients may involve minimizing the supine intraperitoneal fluid volume. However, since achieving adequate dialysis in CAPD/CCPD patients depends in large part on the exchange volume, this strategy may require careful tailoring of the dialysis prescription to attain adequate clearance while simultaneously minimizing symptoms of GERD. (See  <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">"Medical management of gastroesophageal reflux disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1968.html" rel="external">"Prescribing peritoneal dialysis"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Delayed gastric emptying</span><span class="headingEndMark"> — </span>Normal gastrointestinal motor function is a complex series of events that requires coordination of the sympathetic and parasympathetic nervous systems, neurons within the stomach and intestine, and the smooth muscle cells of the gut. Abnormalities of this process may lead to a delay in gastric emptying (gastric stasis), a disorder that occurs commonly in certain diseases, particularly diabetes [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/2638.html" rel="external">"Pathogenesis of delayed gastric emptying"</a>.)</p><p>Delayed gastric emptying is relatively common among CAPD patients, including those without diabetes. </p><p>In a few small studies, delayed gastric emptying of solids and liquids has been detected in approximately 50 percent of both symptomatic and asymptomatic patients undergoing peritoneal dialysis [<a href="#rid8">8-10</a>].</p><p>Normal gastric emptying results have been noted when the peritoneal cavities are drained, thereby suggesting that a mechanical or neurogenic mechanism triggered by the presence of intra-abdominal fluid retards gastric emptying [<a href="#rid8">8</a>] (see  <a class="medical medical_review" href="/z/d/html/2640.html" rel="external">"Gastroparesis: Etiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2638.html" rel="external">"Pathogenesis of delayed gastric emptying"</a>). However, this finding is not consistent across all studies [<a href="#rid11">11,12</a>]. In addition, certain types of dialysates (eg, glucose- or glycerol-based) may have an association with slower gastric emptying [<a href="#rid12">12</a>]. </p><p class="headingAnchor" id="H6"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>First-line therapy for gastroparesis in CAPD/CCPD patients is oral <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a>. However, risks of central nervous system side effects, such as tardive dyskinesia, make this agent less attractive, particularly for long-term use, as is often required among diabetic patients with gastroparesis. In general, the dose of oral metoclopramide should be reduced by 50 to 75 percent in patients with an estimated glomerular filtration rate (eGFR) &lt;10 mL/min/1.73 m<sup>2</sup>. An alternative to metoclopramide is oral <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>. </p><p>In patients whose symptoms persist in spite of oral therapy, intraperitoneal <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> [<a href="#rid13">13,14</a>] or <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> [<a href="#rid15">15,16</a>] can be considered. However, the use of intraperitoneal metoclopramide has not been well studied in CAPD/CCPD patients, and optimal dosing is unclear. One case report used 10 mg of metoclopramide per 2 liter bag of dialysate [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/2532.html" rel="external">"Treatment of gastroparesis"</a>.)</p><p>Historically, the drug <a class="drug drug_general" data-topicid="9269" href="/z/d/drug information/9269.html" rel="external">cisapride</a> had been used to successfully treat delayed gastric emptying in CAPD patients. However, it is no longer used in patients on dialysis due to the risk of arrhythmias associated with this drug.</p><p>In one study, two patients were successfully treated with gastric electrical stimulation, suggesting that this may also be considered in refractory cases [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H277170720"><span class="h2">Intraperitoneal pressure and gastroesophageal problems in peritoneal dialysis patients</span><span class="headingEndMark"> — </span>Intraperitoneal pressures during peritoneal dialysis in the filled state average approximately 12 to 13 mmHg in the supine position and 21 to 22 mmHg in the erect position [<a href="#rid18">18,19</a>]. Intraperitoneal pressure rises linearly with increases in intraperitoneal volume [<a href="#rid19">19</a>]. In one study of 61 peritoneal dialysis patients, a higher body mass index (BMI) was associated with higher intraperitoneal pressure and a higher incidence of enteric peritonitis, but there was no association with hernias, late peritoneal leaks, or GERD [<a href="#rid19">19</a>]. Thus, increased intraperitoneal pressure is likely one of several rather than the sole cause of GERD and hernias in peritoneal dialysis patients.</p><p class="headingAnchor" id="H7"><span class="h1">BACK PAIN</span><span class="headingEndMark"> — </span>Increased mechanical stress on the lumbar spine is common among patients on continuous ambulatory peritoneal dialysis (CAPD); this is due, in part, to the tendency of patients to assume a more lordotic position because of increased intra-abdominal pressure [<a href="#rid20">20</a>]. Some patients may also have poor abdominal muscle tone, resulting from previous surgeries or poor physical conditioning. These effects increase the mechanical stress on the lumbar spine, thereby causing back pain or sciatica [<a href="#rid21">21</a>]. Underlying degenerative disk disease, facet joint disease, and osteoporosis may further exacerbate the back pain [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/7782.html" rel="external">"Evaluation of low back pain in adults"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Other than general therapeutic measures, the treatment of lower back pain in CAPD patients may include decreasing the dialysate fill volume. However, since adequate dialysis <strong>must</strong> be maintained, changing the modality to continuous cycler peritoneal dialysis (CCPD) may be beneficial as larger fill volumes may be tolerated and the majority of dialysate dwells can be performed when the patient is supine. In those whose back pain is severe, transfer to hemodialysis may be necessary if adequate clearance on CCPD cannot be achieved. (See  <a class="medical medical_review" href="/z/d/html/7780.html" rel="external">"Treatment of acute low back pain"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">PLEURAL EFFUSION DUE TO PLEUROPERITONEAL LEAK</span><span class="headingEndMark"> — </span>The development of a pleural effusion (hydrothorax) in a patient on continuous peritoneal dialysis may be due to systemic volume overload, heart failure, or a local pleural process. The presence of a pleural effusion without other signs of heart failure or of peripheral edema, particularly if the effusion is only right sided, should prompt a search for a pleuroperitoneal communication.</p><p class="headingAnchor" id="H10"><span class="h2">Pathophysiology</span><span class="headingEndMark"> — </span>A pleural effusion that results from a pleuroperitoneal leak typically occurs early in the course of therapy and is not related to the volume of instilled dialysate; as a result, congenital communications between the pleura and the peritoneum have been hypothesized to be the source of the leak [<a href="#rid22">22-24</a>]. Diaphragmatic hernias, for example, may allow dissection of fluid through defects around the major vessels and the esophagus or through diaphragmatic foramina [<a href="#rid22">22,23</a>]. In addition, the negative intrathoracic pressure, combined with an increased intra-abdominal pressure caused by dialysate instillation, may open small defects in the diaphragm and promote the flow of dialysate into the pleural space. In autopsy studies, discontinuities in the tendinous portions of the hemidiaphragms have been observed, thereby supporting the presence of diaphragmatic defects [<a href="#rid23">23</a>].</p><p>Acquired diaphragmatic defects may also permit the development of hydrothorax. This is suggested by the finding that acute pleural effusion has been observed as late as eight years after starting peritoneal dialysis.</p><p class="headingAnchor" id="H11"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>The reported incidence of acute pleural effusion in patients being maintained on peritoneal dialysis varies from 1.6 to 10 percent [<a href="#rid22">22,23,25,26</a>]. In the largest study reported to date, 50 of 3195 patients (1.6 percent) developed acute hydrothorax after starting peritoneal dialysis [<a href="#rid22">22</a>]. Women are affected more commonly than men [<a href="#rid25">25</a>].</p><p>Patients with polycystic kidney disease are predisposed to develop pleuroperitoneal leaks. Because of the significantly reduced abdominal capacity of these patients, a marked increase in hydrostatic pressure occurs after the infusion of dialysate, thereby favoring the flow of dialysate from the peritoneum to the chest [<a href="#rid23">23,27</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Clinical characteristics</span><span class="headingEndMark"> — </span>Presenting symptoms and signs of pleural effusion include dyspnea and inadequate ultrafiltration ability [<a href="#rid22">22</a>]. However, many patients are asymptomatic (26 percent), with the recognition of fluid in the pleural space occurring only after routine physical examination [<a href="#rid22">22</a>]. The right side is more commonly affected than the left, with unilateral right-sided effusions found in 50 to 90 percent of cases [<a href="#rid23">23,25</a>].</p><p>Most pleural effusions appear early after the initiation of peritoneal dialysis: 50 percent are found within 30 days of starting peritoneal dialysis, while 20 percent occur after one year [<a href="#rid22">22</a>]. Overall, these effusions have been reported to occur one day to eight years after beginning peritoneal dialysis [<a href="#rid22">22,23,25</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The presence of a pleural effusion resulting from a pleuroperitoneal leak should be suspected in the dyspneic nonedematous patient and in patients in whom ultrafiltration is consistently inadequate. Establishing that fluid in the pleural space is due to a pleuroperitoneal leak is based upon confirming that the fluid is dialysate and that it is leaking from the peritoneum into the pleura. A detailed discussion of the diagnosis and evaluation of this problem is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1929.html" rel="external">"Modalities for the diagnosis of abdominal and thoracic cavity defects in patients on peritoneal dialysis"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Management</span><span class="headingEndMark"> — </span>The treatment of acute hydrothorax due to pleuroperitoneal leaks depends upon the acuity and severity of the patient's symptoms and the need and/or desire to continue with peritoneal dialysis as a treatment modality. Acute thoracentesis to remove large pleural effusions is rarely required. In most cases, simply draining the peritoneal cavity and avoiding overnight (supine) dwells is sufficient. If the leak is small and the patient has adequate residual function to permit intermittent dialysis (eg, nocturnal peritoneal dialysis), peritoneal dialysis can be continued.</p><p>Peritoneal dialysis may also be continued if the estimated duration of dialysis is short, such as the patient who will soon undergo a living, related transplant [<a href="#rid23">23,28</a>]. However, although some pleuroperitoneal leaks spontaneously resolve (often after temporary transfer to hemodialysis), cure rates are, at best, only 40 percent with conservative therapy [<a href="#rid22">22,23,25,29</a>].</p><p>Chemical pleurodesis may be offered to the patient with recurrent pleural effusion, unresponsive to conservative measures, who needs and/or desires to continue with peritoneal dialysis. A paucity of literature exists concerning the effectiveness of such therapy. In one review, pleural effusion resolved after pleurodesis in 67 percent of patients [<a href="#rid30">30</a>]. Agents used have included autologous blood, talc, and <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> [<a href="#rid23">23,31,32</a>]. (See  <a class="medical medical_review" href="/z/d/html/6694.html" rel="external">"Management of nonmalignant pleural effusions in adults"</a>.)</p><p>Although temporary cessation of continuous ambulatory peritoneal dialysis (CAPD) remains the first-line treatment, video-assisted thoracoscopic pleurodesis or repair may also be an option for patients who failed conservative management [<a href="#rid33">33</a>]. Surgical correction of an identified diaphragmatic defect can also be performed but requires thoracotomy [<a href="#rid23">23,34</a>]; this has led some investigators to suggest that thoracoscopy should precede surgery to ensure that a visible, repairable communication is identified.</p><p>Despite these various treatment options, most patients with pleuroperitoneal leaks ultimately require permanent transfer to hemodialysis [<a href="#rid22">22,23,25,29</a>].</p><p class="headingAnchor" id="H15"><span class="h1">HEMOPERITONEUM</span><span class="headingEndMark"> — </span>A discussion of hemoperitoneum in patients undergoing peritoneal dialysis is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1923.html" rel="external">"Bloody peritoneal dialysate (hemoperitoneum)"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">PAIN WITH DIALYSATE INFUSION OR DRAINAGE</span><span class="headingEndMark"> — </span>Abdominal pain often occurs with peritoneal dialysis-associated peritonitis (see  <a class="medical medical_review" href="/z/d/html/1869.html" rel="external">"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis"</a>). This symptom may also occur in the absence of peritonitis, frequently in association with infusion or drainage of dialysate.</p><p class="headingAnchor" id="H1440958429"><span class="h2">Infusion pain</span><span class="headingEndMark"> — </span>Many patients experience pain during infusion of dialysate into the peritoneal cavity that diminishes during the dwell period. This discomfort is frequently transient, resolving shortly after peritoneal dialysis is initiated [<a href="#rid35">35,36</a>]. In some patients, however, abdominal pain during dialysate infusion persists; in extreme situations, it may lead to discontinuation of peritoneal dialysis.</p><p>This complaint is thought to be caused by the acidic pH (pH 5.2 to 5.5) of conventional lactate dialysate. Additional contributing factors may include a poor catheter position (such as abutting against the bowel wall or peritoneal cavity surfaces), the dialysate temperature, and a high glucose concentration of hypertonic dialysis solutions [<a href="#rid36">36</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment of infusion pain includes the following measures, to be utilized in descending order [<a href="#rid36">36</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Raising the dialysate pH, either by using specially formulated solutions or by injecting <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> (2 to 5 mEq/L) into standard dialysate prior to infusion </p><p class="bulletIndent2"><span class="glyph">•</span>Slowing the rate of infusion</p><p class="bulletIndent2"><span class="glyph">•</span>Injection of local anesthetics into the dialysis solution before infusing (1 percent <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> at 50 mg/exchange)</p><p class="bulletIndent2"><span class="glyph">•</span>Incompletely draining the fluid after a dwell period</p><p class="bulletIndent2"><span class="glyph">•</span>Catheter replacement</p><p class="bulletIndent2"><span class="glyph">•</span>Discontinuation of peritoneal dialysis</p><p></p><p>Although injecting <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> into the dialysis solution before infusion may be effective in alleviating pain [<a href="#rid37">37</a>], the risk of contamination during the injection with the subsequent development of peritonitis is high [<a href="#rid36">36</a>]. To avoid this risk, dialysis solutions with a higher pH (pH 7 to 7.4; such as bicarbonate and bicarbonate/lactate dialysis solutions) have been developed.</p><p>The effectiveness of such alternative solutions, compared with conventional lactate solution, has been evaluated in several studies [<a href="#rid36">36,38</a>]. In a randomized, double-blind, crossover study where pain was recorded using two quantifiable scales, significant reductions in inflow pain were noted when the bicarbonate (38 mM) or bicarbonate/lactate (25 mM of bicarbonate/15 mM of lactate) solutions were used as compared with the conventional lactate (40 mM solution) [<a href="#rid36">36</a>]. In this study, the bicarbonate/lactate solution was the most effective in alleviating infusion pain, thereby suggesting that factors other than the pH are involved in infusion pain.</p><p class="headingAnchor" id="H4194393562"><span class="h2">Drain pain</span><span class="headingEndMark"> — </span>Pain that occurs during the draining phase of peritoneal dialysis, or drain pain, is an underreported complication of peritoneal dialysis. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Drain pain is common. A Canadian multicenter study of 293 patients on automated peritoneal dialysis (APD) reported that 72 (25 percent) were using tidal peritoneal dialysis (TPD) due to drain pain [<a href="#rid39">39</a>]. A subsequent international study of 1630 patients on peritoneal dialysis reported that 461 (28 percent) had drain pain [<a href="#rid40">40</a>]. Among patients with pain, over a third rated their pain as severe. </p><p></p><p class="bulletIndent1">Risk factors for drain pain include the use of APD (rather than continuous ambulatory peritoneal dialysis [CAPD]), polycystic kidney disease, and female sex [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – Drain pain in patients on APD is thought to be caused by the cycler, which uses hydraulic pressure to drain dialysate. During drainage, this negative pressure may force the tip of the dialysis catheter against the bowel, bladder, or parietal peritoneum, causing pain. In some cases, it is possible that drain pain in APD may be the result of catheters that are too long and/or malpositioned. In such patients, the end portion of the catheter may lie on or near the floor of the peritoneal cavity, increasing the likelihood that the catheter will be suctioned into the parietal peritoneum during drainage, causing pain. </p><p></p><p class="bulletIndent1">The higher rates of drain pain in patients with polycystic kidney disease and females may be due to diminished peritoneal space (from enlarged kidneys or the uterus) that increases the likelihood of the catheter being pushed into adjacent tissue.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Drain pain predominantly affects patients on APD and presents as mild to severe discomfort in the abdomen or as referred pain in the rectum or perineum. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment – </strong>Our approach to the management of drain pain is based on our clinical experience and includes the following measures, to be utilized in descending order. If an intervention is effective, no further measures are required.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Empiric treatment with laxatives. Successful treatment of even mild constipation may reposition the catheter and improve drain pain.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initiation of TPD. TPD leaves some peritoneal fluid in the abdomen with every cycle, which may reduce pain by preventing contact of the catheter with the viscera or parietal peritoneum. (See  <a class="medical medical_review" href="/z/d/html/1858.html" rel="external">"Evaluating patients for chronic peritoneal dialysis and selection of modality"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evaluation of the dialysis catheter with an abdominal radiograph. Patients who have a catheter that is too long and/or malpositioned should be referred to interventional nephrology/radiology or surgery. In some patients, catheter replacement or repositioning may improve or eliminate drain pain.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Switching from APD to CAPD. CAPD may be effective reducing pain since it uses gravity rather than a cycler to drain dialysate.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discontinuation of peritoneal dialysis.</p><p></p><p class="bulletIndent1">There is no evidence that adding bicarbonate or catheter design (straight versus coiled) has any impact on drain pain. </p><p></p><p class="headingAnchor" id="H18"><span class="h1">ELECTROLYTE ABNORMALITIES</span><span class="headingEndMark"> — </span>Although any disturbance in electrolyte concentration may occur among peritoneal dialysis patients, abnormalities in serum levels of potassium and magnesium are most commonly observed.</p><p class="headingAnchor" id="H19"><span class="h2">Hypokalemia</span><span class="headingEndMark"> — </span>Unlike chronic hemodialysis patients, in whom hyperkalemia is more common than hypokalemia, 10 to 35 percent of patients on continuous peritoneal dialysis require potassium supplements [<a href="#rid41">41-43</a>]. A retrospective study of 45 continuous ambulatory peritoneal dialysis (CAPD)/continuous cycler peritoneal dialysis (CCPD) patients found that approximately 30 percent required oral <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a> supplementation with a mean dose of 22±13 mEq/day [<a href="#rid41">41</a>]. Hypokalemic patients complained of weakness more often than those with normal potassium levels. African American race was a predictor of the need for potassium supplementation, but Kt/V, etiology of kidney failure, age, peritoneal membrane transport type, and oral protein and caloric intake were not. Cultural dietary preferences were thought to be responsible for these findings. A Chinese study of 886 peritoneal dialysis patients found hypokalemia in 27.9 percent [<a href="#rid44">44</a>]. Cellular uptake of potassium, prompted by the intraperitoneal glucose load with subsequent insulin release, and bowel losses may also play a role in the hypokalemia observed in peritoneal dialysis patients [<a href="#rid45">45</a>].</p><p>For stable chronic outpatients, liberalization of dietary potassium restriction and, when needed, oral potassium replacement (usually 20 mEq/day, based upon individual patient serum potassium determinations) are usually successful treatments for hypokalemia. Potassium-sparing diuretics like <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> may also be effective in the peritoneal dialysis patient with chronic hypokalemia with appropriate surveillance of serum potassium levels [<a href="#rid46">46</a>]. Intraperitoneal potassium may also be administered acutely if critical hypokalemia exists [<a href="#rid47">47</a>]. Although intraperitoneal potassium can correct hypokalemia in stable outpatients on peritoneal dialysis [<a href="#rid48">48</a>], we recommend that oral potassium supplements be used rather than intraperitoneal potassium due to the risk of contamination (and subsequently peritonitis) when intraperitoneal instillation is required.</p><p>An association of hypokalemia with mortality has been observed among peritoneal dialysis patients and suggests that hypokalemia should be recognized and treated appropriately [<a href="#rid44">44,49</a>]. The Chinese study of 886 incident peritoneal dialysis patients found a U-shaped association of baseline serum potassium levels and all-cause and cardiovascular mortality, with the highest mortality among patients with potassium &lt;3 mEq/L [<a href="#rid44">44</a>]. This observed relationship was only evident during the first year of dialysis and not in subsequent years.</p><p>A similar U-shaped relationship of serum potassium &lt;3.5 mEq/L and all-cause and cardiovascular mortality was observed in a US study that showed the lowest mortality in patients with serum potassium of 4 to 4.5 mEq/L [<a href="#rid49">49</a>]. A Brazilian study of 306 hypokalemic peritoneal dialysis patients (time-averaged serum potassium &lt;3.5 mEq/L) compared with a control group of 1512 peritoneal dialysis patients with normal time-averaged potassium levels also found a U-shaped relationship between time-averaged serum potassium and all-cause mortality [<a href="#rid50">50</a>]. In this study, hypokalemia was associated with a 49 percent increased risk for cardiovascular mortality [<a href="#rid50">50</a>]. Hypokalemia was also associated with a higher mortality due to non–peritoneal dialysis–related infections; there was no association of hypokalemia with peritonitis [<a href="#rid50">50</a>]. Increased mortality in hypokalemic peritoneal dialysis patients was demonstrated to be independent of the use of potassium supplementation in a study of 108 patients receiving potassium supplements compared with 114 control patients [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H20"><span class="h2">Hypermagnesemia and hypomagnesemia</span><span class="headingEndMark"> — </span>Hypermagnesemia, a common finding in peritoneal dialysis patients, is due to positive magnesium balance resulting from kidney failure and the relatively high dialysate magnesium concentration (see  <a class="medical medical_review" href="/z/d/html/844.html" rel="external">"Regulation of magnesium balance"</a> and  <a class="medical medical_review" href="/z/d/html/831.html" rel="external">"Hypermagnesemia: Causes, symptoms, and treatment"</a>). Serum magnesium levels are usually elevated in those dialyzed against solutions containing magnesium concentrations of 0.75 mmol/L (1.8 mg/dL) [<a href="#rid52">52,53</a>].</p><p>The typical serum magnesium level in end-stage kidney disease (ESKD) patients is 2.4 to 3.6 mg/dL (1 to 1.5 mmol/L), a value usually not associated with clinical symptoms (see  <a class="medical medical_review" href="/z/d/html/831.html" rel="external">"Hypermagnesemia: Causes, symptoms, and treatment"</a>). However, an inverse relationship between concentrations of magnesium and intact parathyroid hormone (PTH) raises the possibility that hypermagnesemia suppresses PTH levels, thereby contributing to adynamic bone disease in peritoneal dialysis patients [<a href="#rid52">52</a>]. As a result, although abnormalities in calcium, vitamin D, and phosphorus metabolism are the primary factors, more attention should be focused upon the role of magnesium in leading to the relative high incidence of adynamic bone disease in peritoneal dialysis patients. (See  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>.) </p><p>In addition, multiple factors can affect plasma magnesium concentration including diet, nutritional status, albumin levels, medications like proton pump inhibitors, magnesium-containing laxatives, and dialysis prescriptions [<a href="#rid54">54</a>]. Little is known about hypo- and hypermagnesemia among dialysis patients, especially on cardiovascular status and mortality, and more study of this cation in relation to dialysis is needed [<a href="#rid54">54,55</a>].</p><p>Current <a class="drug drug_general" data-topicid="113932" href="/z/d/drug information/113932.html" rel="external">peritoneal dialysis solutions</a> contain magnesium concentrations of 0.75, 0.5, and 0.25 mmol/L (1.8, 1.2, and 0.6 mg/dL). As some patients utilizing the 0.25 mmol/L (0.6 mg/dL) magnesium concentration become hypomagnesemic, the 0.5 mmol/L (1.2 mg/dL) concentration dialysate may be the better choice [<a href="#rid53">53</a>].</p><p>Magnesium clearance in peritoneal dialysis patients likely also varies, in part, based on the presence or absence of residual kidney function and the characteristics of the individual's peritoneal membrane [<a href="#rid56">56</a>]. In one study of 115 peritoneal dialysis patients, for example, peritoneal magnesium clearance positively correlated with nutritional status, daily peritoneal protein loss, and high transport membrane type [<a href="#rid56">56</a>].</p><p>Given that many peritoneal dialysis patients are slightly hypermagnesemic, the use of magnesium-containing antacids as phosphate binders is rarely a useful clinical option.</p><p>Studies have demonstrated an association of mortality with hypomagnesemia among peritoneal dialysis patients [<a href="#rid57">57,58</a>]. A single-center, retrospective study of 253 incident peritoneal dialysis patients found that 14.2 percent were hypomagnesemic [<a href="#rid57">57</a>]. Peritoneal dialysis duration and hypoalbuminemia were associated with low magnesium levels in these patients who also had a higher mortality and cardiovascular mortality [<a href="#rid57">57</a>]. A large cohort study of 10,692 incident peritoneal dialysis patients beginning peritoneal dialysis between January 2007 and December 2011 found that 18 percent of patients had a serum magnesium level &lt;1.8 mg/dL, 21 percent had a magnesium level of 1.8 to 2.0 mg/dL, and only 19 percent had a level ≥2.4 mg/dL [<a href="#rid58">58</a>]. Patients with magnesium level &lt;1.8 mg/dL had a higher risk of hospitalization (HR 1.23) and a higher risk of death (HR 1.21). The greatest risk for hospitalization was in hypomagnesemic patients with a serum albumin &lt;3.5 mg/dL [<a href="#rid58">58</a>]. Thus, emerging evidence suggests that up to a quarter of peritoneal dialysis patients are hypomagnesemic and that hypomagnesemia may be a mortality risk factor in this patient population. Additional study of these issues is needed.</p><p class="headingAnchor" id="H3141219323"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H13318460"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/4426.html" rel="external">"Patient education: Peritoneal dialysis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3409435"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Noninfectious complications of peritoneal dialysis</strong> – Noninfectious complications occurring in patients undergoing either continuous ambulatory peritoneal dialysis (CAPD) or continuous cycler peritoneal dialysis (CCPD) are often a consequence of increased intra-abdominal pressure resulting from instillation of dialysate into the peritoneal cavity. These include gastroesophageal reflux and delayed gastric emptying, back and abdominal pain, and pleural effusion. Additional common issues observed in peritoneal dialysis patients include hemoperitoneum, pain with dialysate infusion or drainage, hypokalemia, and dysmagnesemia. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal complications</strong> – Gastroesophageal reflux and delayed gastric emptying should be considered in well-dialyzed patients complaining of nausea, vomiting, fullness, and epigastric discomfort. In addition to general measures, the treatment of gastroesophageal reflux in CAPD/CCPD patients may involve minimizing the supine intraperitoneal fluid volume. However, since achieving adequate dialysis in CAPD/CCPD patients depends in large part on the exchange volume, this strategy may require careful tailoring of the dialysis prescription to avoid inadequate small-solute clearance, especially since there is no clear association of increased intra-abdominal pressure with the occurrence of gastroesophageal reflux disease (GERD) in small studies of peritoneal dialysis patients. (See <a class="local">'Gastroesophageal reflux disease and delayed gastric emptying'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pleuroperitoneal leak</strong> – A pleuroperitoneal leak should be considered in peritoneal dialysis patients with pleural effusion (especially right-sided effusion) without other signs of heart failure. A number of different measures can be utilized based upon severity and underlying cause. (See <a class="local">'Pleural effusion due to pleuroperitoneal leak'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain with dialysate infusion or drainage</strong> – Abdominal pain in a peritoneal dialysis patient should prompt consideration of peritonitis, catheter malfunction, or possibly infusion or drain pain. Infusion pain may be treated with intraperitoneal infusion of bicarbonate. We take a stepwise approach to the management of drain pain. (See <a class="local">'Pain with dialysate infusion or drainage'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypokalemia</strong> – Unlike hemodialysis patients, hypokalemia is fairly common in peritoneal dialysis patients and is likely associated with all-cause and cardiovascular mortality in a U-shaped manner. Liberalization of dietary potassium, and often prescription of oral potassium supplements, may be needed. Medications that promote hyperkalemia such as the potassium-sparing diuretics (eg, <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>) may be useful. (See <a class="local">'Electrolyte abnormalities'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Magnesium disorders</strong> – Although hypermagnesemia is the predominant problem in patients with kidney failure, hypomagnesemia has been observed in a significant percentage of peritoneal dialysis patients and may be associated with hospitalization and mortality. Magnesium levels should be monitored and dialysate magnesium concentration adjusted to maintain normal levels. (See <a class="local">'Hypermagnesemia and hypomagnesemia'</a> above.)</p><p></p><p class="headingAnchor" id="H1502929530"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jean L Holley, MD, FACP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Björvell H, Hylander B. Functional status and personality in patients on chronic dialysis. J Intern Med 1989; 226:319.</a></li><li><a class="nounderline abstract_t">Dong R, Guo ZY. Gastrointestinal symptoms in patients undergoing peritoneal dialysis: multivariate analysis of correlated factors. World J Gastroenterol 2010; 16:2812.</a></li><li><a class="nounderline abstract_t">Kosmadakis G, Albaret J, da Costa Correia E, et al. Gastrointestinal Disorders in Peritoneal Dialysis Patients. Am J Nephrol 2018; 48:319.</a></li><li><a class="nounderline abstract_t">Hylander BI, Dalton CB, Castell DO, et al. Effect of intraperitoneal fluid volume changes on esophageal pressures: studies in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1991; 17:307.</a></li><li><a class="nounderline abstract_t">Kim MJ, Kwon KH, Lee SW. Gastroesophageal reflux disease in CAPD patients. Adv Perit Dial 1998; 14:98.</a></li><li><a class="nounderline abstract_t">Lee YC, Hung SY, Wang HH, et al. Different Risk of Common Gastrointestinal Disease Between Groups Undergoing Hemodialysis or Peritoneal Dialysis or With Non-End Stage Renal Disease: A Nationwide Population-Based Cohort Study. Medicine (Baltimore) 2015; 94:e1482.</a></li><li><a class="nounderline abstract_t">Keshavarzian A, Iber FL, Vaeth J. Gastric emptying in patients with insulin-requiring diabetes mellitus. Am J Gastroenterol 1987; 82:29.</a></li><li><a class="nounderline abstract_t">Brown-Cartwright D, Smith HJ, Feldman M. Gastric emptying of an indigestible solid in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis. Gastroenterology 1988; 95:49.</a></li><li><a class="nounderline abstract_t">Bird NJ, Streather CP, O'Doherty MJ, et al. Gastric emptying in patients with chronic renal failure on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1994; 9:287.</a></li><li><a class="nounderline abstract_t">Fernström A, Hylander B, Grybäck P, et al. Gastric emptying and electrogastrography in patients on CAPD. Perit Dial Int 1999; 19:429.</a></li><li><a class="nounderline abstract_t">Hubalewska A, Stompór T, Płaczkiewicz E, et al. Evaluation of gastric emptying in patients with chronic renal failure on continuous ambulatory peritoneal dialysis using 99mTc-solid meal. Nucl Med Rev Cent East Eur 2004; 7:27.</a></li><li><a class="nounderline abstract_t">Van V, Schoonjans RS, Struijk DG, et al. Influence of dialysate on gastric emptying time in peritoneal dialysis patients. Perit Dial Int 2002; 22:32.</a></li><li><a class="nounderline abstract_t">Seibert DG, Moss AH, Holley JL, Foulks CJ. Intraperitoneal metoclopramide improves symptoms of gastroparesis in a CAPD patient. Perit Dial Int 1989; 9:223.</a></li><li><a class="nounderline abstract_t">Moss AH. Therapy for diabetic gastroparesis. Semin Dial 1991; 4:125.</a></li><li><a class="nounderline abstract_t">Wadhwa NK, Atkins H, Cabralda T. Intraperitoneal erythromycin for gastroparesis. Ann Intern Med 1991; 114:912.</a></li><li><a class="nounderline abstract_t">Gallar P, Oliet A, Vigil A, et al. Gastroparesis: an important cause of hospitalization in continuous ambulatory peritoneal dialysis patients and the role of erythromycin. Perit Dial Int 1993; 13 Suppl 2:S183.</a></li><li><a class="nounderline abstract_t">Majanović SK, Zelić M, Belančić A, et al. Gastric Electrical Stimulation Improves Symptoms of Diabetic Gastroparesis in Patients on Peritoneal Dialysis-2 Case Reports. Perit Dial Int 2018; 38:458.</a></li><li><a class="nounderline abstract_t">Al-Hwiesh A, Al-Mueilo S, Saeed I, Al-Muhanna FA. Intraperitoneal pressure and intra-abdominal pressure: are they the same? Perit Dial Int 2011; 31:315.</a></li><li><a class="nounderline abstract_t">Dejardin A, Robert A, Goffin E. Intraperitoneal pressure in PD patients: relationship to intraperitoneal volume, body size and PD-related complications. Nephrol Dial Transplant 2007; 22:1437.</a></li><li><a class="nounderline abstract_t">Bargman JM. Complications of peritoneal dialysis related to increased intraabdominal pressure. Kidney Int Suppl 1993; 40:S75.</a></li><li><a class="nounderline abstract_t">Homodraka-Malis A. Pathogenesis and treatment of back pain in peritoneal dialysis patients. Perit Dial Bull 1983; 3(Suppl 3):S41.</a></li><li><a class="nounderline abstract_t">Nomoto Y, Suga T, Nakajima K, et al. Acute hydrothorax in continuous ambulatory peritoneal dialysis--a collaborative study of 161 centers. Am J Nephrol 1989; 9:363.</a></li><li><a class="nounderline abstract_t">García Ramón R, Carrasco AM. Hydrothorax in peritoneal dialysis. Perit Dial Int 1998; 18:5.</a></li><li><a class="nounderline abstract_t">Lew SQ. Hydrothorax: pleural effusion associated with peritoneal dialysis. Perit Dial Int 2010; 30:13.</a></li><li><a class="nounderline abstract_t">Abraham G, Shokker A, Blake P, Oreopoulos DG. Massive hydrothorax in patients on peritoneal dialysis: A literature review. Adv Perit Dial 1988; 4:121.</a></li><li><a class="nounderline abstract_t">Shemin D, Clark DD, Chazan JA. Unexplained pleural effusions in the peritoneal dialysis population. Perit Dial Int 1989; 9:143.</a></li><li><a class="nounderline abstract_t">Fletcher S, Turney JH, Brownjohn AM. Increased incidence of hydrothorax complicating peritoneal dialysis in patients with adult polycystic kidney disease. Nephrol Dial Transplant 1994; 9:832.</a></li><li><a class="nounderline abstract_t">Christidou F, Vayonas G. Recurrent acute hydrothorax in a CAPD patient: successful management with small volumes of dialysate. Perit Dial Int 1995; 15:389.</a></li><li><a class="nounderline abstract_t">Simmons LE, Mir AR. A review of management of pleuroperitoneal communication in five CAPD patients. Adv Perit Dial 1989; 5:81.</a></li><li><a class="nounderline abstract_t">Sudduth CD, Sahn SA. Pleurodesis for nonmalignant pleural effusions. Recommendations. Chest 1992; 102:1855.</a></li><li><a class="nounderline abstract_t">Hidai H, Takatsu S, Chiba T. Intrathoracic instillation of autologous blood in treating massive hydrothorax following CAPD. Perit Dial Int 1989; 9:221.</a></li><li><a class="nounderline abstract_t">Kanaan N, Pieters T, Jamar F, Goffin E. Hydrothorax complicating continuous ambulatory peritoneal dialysis: successful management with talc pleurodesis under thoracoscopy. Nephrol Dial Transplant 1999; 14:1590.</a></li><li><a class="nounderline abstract_t">Szeto CC, Chow KM. Pathogenesis and management of hydrothorax complicating peritoneal dialysis. Curr Opin Pulm Med 2004; 10:315.</a></li><li><a class="nounderline abstract_t">Pattison CW, Rodger RS, Adu D, et al. Surgical treatment of hydrothorax complicating continuous ambulatory peritoneal dialysis. Clin Nephrol 1984; 21:191.</a></li><li><a class="nounderline abstract_t">Vaamonde CA, Michael UF, Metzger RA, Carroll KE Jr. Complications of acute peritoneal dialysis. J Chronic Dis 1975; 28:637.</a></li><li><a class="nounderline abstract_t">Mactier RA, Sprosen TS, Gokal R, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998; 53:1061.</a></li><li><a class="nounderline abstract_t">Bunchman TE, Ballal SH. Treatment of inflow pain by pH adjustment of dialysate in peritoneal dialysis. Perit Dial Int 1991; 11:179.</a></li><li><a class="nounderline abstract_t">Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution--clinical benefits. The Bicarbonate/Lactate Study Group. Perit Dial Int 2000; 20:516.</a></li><li><a class="nounderline abstract_t">Blake PG, Sloand JA, McMurray S, et al. A multicenter survey of why and how tidal peritoneal dialysis (TPD) is being used. Perit Dial Int 2014; 34:458.</a></li><li><a class="nounderline abstract_t">Aga Z, McCullough K, Pisoni RL, et al. Peritoneal Dialysis-Related Drain Pain and Patient and Treatment Characteristics: Findings From the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). Am J Kidney Dis 2023; 82:779.</a></li><li><a class="nounderline abstract_t">Khan AN, Bernardini J, Johnston JR, Piraino B. Hypokalemia in peritoneal dialysis patients. Perit Dial Int 1996; 16:652.</a></li><li><a class="nounderline abstract_t">Oreopoulos DG, Khanna R, Williams P, Vas SI. Continuous ambulatory peritoneal dialysis - 1981. Nephron 1982; 30:293.</a></li><li><a class="nounderline abstract_t">Spital A, Sterns RH. Potassium supplementation via the dialysate in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1985; 6:173.</a></li><li><a class="nounderline abstract_t">Xu Q, Xu F, Fan L, et al. Serum potassium levels and its variability in incident peritoneal dialysis patients: associations with mortality. PLoS One 2014; 9:e86750.</a></li><li><a class="nounderline abstract_t">Tziviskou E, Musso C, Bellizzi V, et al. Prevalence and pathogenesis of hypokalemia in patients on chronic peritoneal dialysis: one center's experience and review of the literature. Int Urol Nephrol 2003; 35:429.</a></li><li><a class="nounderline abstract_t">Fülöp T, Zsom L, Rodríguez B, et al. Clinical Utility of Potassium-Sparing Diuretics to Maintain Normal Serum Potassium in Peritoneal Dialysis Patients. Perit Dial Int 2017; 37:63.</a></li><li class="breakAll">Bargman, JM. Noninfectious complications of peritoneal dialysis. In: The Textbook of Peritoneal Dialysis, Gokal, R, Nolph, KD (Eds), Kluwer, Boston 1994. p.555.</li><li><a class="nounderline abstract_t">Amirmokri P, Morgan P, Bastani B. Intra-peritoneal administration of potassium and magnesium: a practical method to supplement these electrolytes in peritoneal dialysis patients. Ren Fail 2007; 29:603.</a></li><li><a class="nounderline abstract_t">Torlén K, Kalantar-Zadeh K, Molnar MZ, et al. Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort. Clin J Am Soc Nephrol 2012; 7:1272.</a></li><li><a class="nounderline abstract_t">Ribeiro SC, Figueiredo AE, Barretti P, et al. Low Serum Potassium Levels Increase the Infectious-Caused Mortality in Peritoneal Dialysis Patients: A Propensity-Matched Score Study. PLoS One 2015; 10:e0127453.</a></li><li><a class="nounderline abstract_t">Zhang YF, Wang Q, Su YY, et al. Potassium supplementation and long-term outcomes in chronic peritoneal dialysis patients with end-stage renal disease: a propensity score matching study. Ren Fail 2016; 38:1594.</a></li><li><a class="nounderline abstract_t">Navarro JF, Mora C, García J, et al. Hypermagnesemia in CAPD. Relationship with parathyroid hormone levels. Perit Dial Int 1998; 18:77.</a></li><li><a class="nounderline abstract_t">Hutchinson AJ. Serum magnesium and end-stage renal disease. Perit Dial Int 1997; 17:327.</a></li><li><a class="nounderline abstract_t">Alhosaini M, Leehey DJ. Magnesium and Dialysis: The Neglected Cation. Am J Kidney Dis 2015; 66:523.</a></li><li><a class="nounderline abstract_t">Fein P, Weiss S, Ramos F, et al. Serum magnesium concentration is a significant predictor of mortality in peritoneal dialysis patients. Adv Perit Dial 2014; 30:90.</a></li><li><a class="nounderline abstract_t">Li G, Zhang L, Ren H, et al. Clearance of Magnesium in Peritoneal Dialysis Patients: A Single-Center Study. Blood Purif 2019; 47 Suppl 1:1.</a></li><li><a class="nounderline abstract_t">Cai K, Luo Q, Dai Z, et al. Hypomagnesemia Is Associated with Increased Mortality among Peritoneal Dialysis Patients. PLoS One 2016; 11:e0152488.</a></li><li><a class="nounderline abstract_t">Yang X, Soohoo M, Streja E, et al. Serum Magnesium Levels and Hospitalization and Mortality in Incident Peritoneal Dialysis Patients: A Cohort Study. Am J Kidney Dis 2016; 68:619.</a></li></ol></div><div id="topicVersionRevision">Topic 1890 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2809507" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Functional status and personality in patients on chronic dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20533603" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Gastrointestinal symptoms in patients undergoing peritoneal dialysis: multivariate analysis of correlated factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30343294" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Gastrointestinal Disorders in Peritoneal Dialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1996574" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effect of intraperitoneal fluid volume changes on esophageal pressures: studies in patients on continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10649702" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gastroesophageal reflux disease in CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26356710" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Different Risk of Common Gastrointestinal Disease Between Groups Undergoing Hemodialysis or Peritoneal Dialysis or With Non-End Stage Renal Disease: A Nationwide Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3799578" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Gastric emptying in patients with insulin-requiring diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3371624" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Gastric emptying of an indigestible solid in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8052437" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Gastric emptying in patients with chronic renal failure on continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11379855" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Gastric emptying and electrogastrography in patients on CAPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15318307" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Evaluation of gastric emptying in patients with chronic renal failure on continuous ambulatory peritoneal dialysis using 99mTc-solid meal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11929141" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Influence of dialysate on gastric emptying time in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2488370" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Intraperitoneal metoclopramide improves symptoms of gastroparesis in a CAPD patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Therapy for diabetic gastroparesis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2014956" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intraperitoneal erythromycin for gastroparesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399560" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Gastroparesis: an important cause of hospitalization in continuous ambulatory peritoneal dialysis patients and the role of erythromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30413639" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Gastric Electrical Stimulation Improves Symptoms of Diabetic Gastroparesis in Patients on Peritoneal Dialysis-2 Case Reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21357935" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Intraperitoneal pressure and intra-abdominal pressure: are they the same?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17308323" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Intraperitoneal pressure in PD patients: relationship to intraperitoneal volume, body size and PD-related complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8445842" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Complications of peritoneal dialysis related to increased intraabdominal pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pathogenesis and treatment of back pain in peritoneal dialysis patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2679094" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Acute hydrothorax in continuous ambulatory peritoneal dialysis--a collaborative study of 161 centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9527025" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hydrothorax in peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20056973" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hydrothorax: pleural effusion associated with peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Massive hydrothorax in patients on peritoneal dialysis: A literature review</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2488201" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Unexplained pleural effusions in the peritoneal dialysis population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7970129" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Increased incidence of hydrothorax complicating peritoneal dialysis in patients with adult polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8785245" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Recurrent acute hydrothorax in a CAPD patient: successful management with small volumes of dialysate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2577434" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A review of management of pleuroperitoneal communication in five CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1446502" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pleurodesis for nonmalignant pleural effusions. Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2562785" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Intrathoracic instillation of autologous blood in treating massive hydrothorax following CAPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10383035" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hydrothorax complicating continuous ambulatory peritoneal dialysis: successful management with talc pleurodesis under thoracoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220759" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pathogenesis and management of hydrothorax complicating peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6705282" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Surgical treatment of hydrothorax complicating continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1206087" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Complications of acute peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9551418" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1649645" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Treatment of inflow pain by pH adjustment of dialysate in peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11117242" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution--clinical benefits. The Bicarbonate/Lactate Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24991054" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A multicenter survey of why and how tidal peritoneal dialysis (TPD) is being used.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37393052" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Peritoneal Dialysis-Related Drain Pain and Patient and Treatment Characteristics: Findings From the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8981546" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hypokalemia in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7110460" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Continuous ambulatory peritoneal dialysis - 1981.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3898826" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Potassium supplementation via the dialysate in continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24475176" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Serum potassium levels and its variability in incident peritoneal dialysis patients: associations with mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15160552" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prevalence and pathogenesis of hypokalemia in patients on chronic peritoneal dialysis: one center's experience and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27282853" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical Utility of Potassium-Sparing Diuretics to Maintain Normal Serum Potassium in Peritoneal Dialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27282853" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical Utility of Potassium-Sparing Diuretics to Maintain Normal Serum Potassium in Peritoneal Dialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17654324" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Intra-peritoneal administration of potassium and magnesium: a practical method to supplement these electrolytes in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22626960" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26091005" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Low Serum Potassium Levels Increase the Infectious-Caused Mortality in Peritoneal Dialysis Patients: A Propensity-Matched Score Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27771983" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Potassium supplementation and long-term outcomes in chronic peritoneal dialysis patients with end-stage renal disease: a propensity score matching study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9527035" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hypermagnesemia in CAPD. Relationship with parathyroid hormone levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9284456" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Serum magnesium and end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25864370" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Magnesium and Dialysis: The Neglected Cation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25338428" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Serum magnesium concentration is a significant predictor of mortality in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30699418" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clearance of Magnesium in Peritoneal Dialysis Patients: A Single-Center Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27023783" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hypomagnesemia Is Associated with Increased Mortality among Peritoneal Dialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27261330" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Serum Magnesium Levels and Hospitalization and Mortality in Incident Peritoneal Dialysis Patients: A Cohort Study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
